Navigation Links
Experimental treatments restore partial vision to blind people
Date:10/20/2009

Two experimental treatments, a retinal prosthesis and fetal tissue transplant, restored some vision to people with blinding eye diseases. The findings, presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health, may lead to new treatments for the blind. Researchers also reported that an engineered protein restored vision in an animal model and identified ways to improve stem cell treatments.

The new studies tested both people and animals with two degenerative eye diseases: retinitis pigmentosa and age-related macular degeneration. These diseases destroy the light-sensitive nerve cells in the retina, leading to blindness. In all, vision loss and eye disease affect 3.6 million Americans and cost the United States $68 billion each year.

Research released today shows that:

  • A retinal prosthesis restores partial vision to people who are totally blind. The prosthesis, made of an array of electrodes, transmits visual information captured by a video camera (Jessy Dorn, PhD, abstract 216.6, see attached summary).

  • Transplanted "sheets" of fetal retinal cells improve visual acuity in several people with retinitis pigmentosa and age-related macular degeneration (Robert B. Aramant, PhD, abstract 837.12, see attached summary).

  • Engineered, light-sensitive proteins restore vision in a mouse study of retinitis pigmentosa. The findings could lead to new treatments for people with degenerative retinal diseases (Natalia Caporale, PhD, abstract 806.10, see attached summary).

  • As researchers strive to develop stem cell therapies for eye disease, a new method increases the yield of retinal cells from human stem cells derived from both embryonic and adult tissue (Jason S. Meyer, PhD, abstract 113.1, see attached summary).

"Basic neuroscience research has formed the basis for significant progress in treating eye disease," said press conference moderator Rachel O. L. Wong, PhD, of the University of Washington, an expert on visual system development. "These studies would not be possible without technological advances and basic science research that continues to explain the normal function and development of the visual system," Wong said.


'/>"/>

Contact: Kat Snodgrass
ksnodgrass@sfn.org
202-299-7957
Society for Neuroscience
Source:Eurekalert

Related biology news :

1. Experimental Biology 2008 meets in San Diego April 5-9
2. Translational research patented first experimental treatment against idiopathic pulmonary fibrosis
3. Experimental Biology and Medicine announces expansion into Asia, opens new office
4. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
5. French scientist wins the Journal of Experimental Biology Outstanding Paper Prize
6. Survival in a Changing World: The Journal of Experimental Biology 2009 symposium
7. 40 minority scientists receive travel fellowships to Experimental Biology 2009 in New Orleans
8. Experimental treatment halts hypoxic-ischemic brain injury in newborns
9. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
10. Paradigm shift in Alzheimerss research: new treatments
11. NIH selects LIAI for major study on allergy molecular causes and possible treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... RADNOR, Pa., Feb. 24, 2017  VWR Corporation (NASDAQ: VWR), ... to laboratory and production customers, today reported its financial results ... 2016. Highlights: 4Q16 record ... up 1.0% on an organic basis. ... on an organic basis, while the Americas net sales increased ...
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
Breaking Biology Technology: